You are here: Industry Insights > placebo

News List

Positive effects of psychedelic microdosing likely due to placebo effect, finds study europeanpharmaceuticalreview
March 04, 2021
The largest placebo-controlled psychedelics study to date concluded that the psychological benefits of microdoses of psychedelics are likely due to the placebo effect.
Peginterferon-lambda accelerates COVID-19 recovery, finds trial europeanpharmaceuticalreview
February 09, 2021
Peginterferon-lambda rapidly reduced non-hospitalised COVID-19 patients’ viral loads and expedited their recovery in a Phase II study.
Bamlanivimab Reduced Risk of COVID-19 at Nursing Homes in Phase 3 Trial americanpharmaceuticalreview
January 22, 2021
Bamlanivimab (LY-CoV555) significantly reduced the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities, Eli Lilly and Company announced.
Merck’s Gefapixant (45 mg Twice Daily) Significantly Decreased Cough Frequency Compared to Placebo at Week 12 and 24 in Patients with Refractory or Unexplained Chronic Cough drugs.com
September 24, 2020
Merck (NYSE: MRK), known as MSD outside the United States and Canada, has announced the results from two pivotal Phase 3 trials (COUGH-1 and COUGH-2) evaluating the efficacy and safety of gefapixant...
Hydroxychloroquine fails as postexposure prophylaxis for COVID-19 pharmatimes
June 08, 2020
Researchers have found that giving hydroxychloroquine as postexposure prophylaxis for COVID-19 did not prevent illness.
MIV-711 No Better Than Placebo for Pain Relief in Knee OA drugs
January 02, 2020
A novel cathepsin K inhibitor, MIV-711, is no more effective than placebo for reducing pain in patients with symptomatic ...
Vitamin D Supplementation Offers No Benefit for Critically Ill drugs
December 24, 2019
For critically ill, vitamin D-deficient patients, early administration of high-dose enteral vitamin D3, compared with placebo, does not improve 90-day mortality or other outcomes ...
SAE Rate Higher With Nilotinib Versus Placebo in Parkinson Disease drugs
December 18, 2019
Among patients with moderately severe Parkinson disease, exploratory biomarkers are altered in response to nilotinib, but the rate of serious adverse events (SAEs) is significantly higher in ...
Liraglutide Ups Risk for Gallbladder, Biliary Tract Events drugs
August 27, 2019
There is an increased risk for gallbladder- or biliary tract-related events among patients with type 2 diabetes taking liraglutide versus placebo, according to a study published online in Diabetes Care.
Filgotinib Bests Placebo in Tx of Refractory Rheumatoid Arthritis drugs
July 24, 2019
Among patients with moderately to severely active rheumatoid arthritis (RA) resistant to previous therapy with biologic agents...

Previous page 1 2 3 Next page